Androtriol injection for recent acute stroke treatment
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests whether a new medication called androtriol, given as an injection, helps people recover from a recent moderate-to-severe stroke caused by a blocked blood vessel. The medication is given within 24 hours of the stroke, along with standard procedures to open the blocked vessel, to see if it can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 80 years
- Had a stroke due to a blocked blood vessel in the brain and are planning or have already had a procedure to open that vessel
- Can receive the study medication within 24 hours of stroke onset
- Have a moderate to severe stroke, with a score of at least 6 on a standard stroke scale
- No bleeding in the brain, and no severe kidney or liver problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug, QHRD106, given as an injection for people who have had a moderate-to-severe acute ischemic stroke. It aims to see if the drug can help recovery when given within 24 hours after the stroke starts, and it is for patients who are not receiving standard clot-busting treatment.
This trial tests whether a drug called urinary kallidinogenase can help people who have had a stroke caused by a blocked artery in the brain. The drug is given within 48 hours of the stroke, and the study hopes to see if it improves recovery and reduces disability.
This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.
This Phase 2 study tests LT3001 to improve recovery after an acute ischemic stroke (a stroke caused by blocked blood flow). It is designed for people who can be treated within 24 hours of symptom onset and who meet specific safety and health requirements.
This study tests whether a clot-busting drug called pro-urokinase can help people with a stroke in the back of the brain when given later than usual (4.5 to 9 hours after symptoms start). The goal is to see if it improves recovery and reduces disability.
This study tests an investigational injectable drug called LT3001 that may help dissolve blood clots in the brain after a stroke. It is given within 24 hours of stroke onset, and the goal is to reduce disability and improve recovery.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.